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Abstract
Background:  Artemisinin combination therapy (ACT) has been widely adopted as first-line
treatment for uncomplicated falciparum malaria. In Uganda, amodiaquine plus artesunate (AQ+AS),
is the alternative first-line regimen to Coartem® (artemether + lumefantrine) for the treatment of
uncomplicated falciparum malaria. Currently, there are few field-adapted analytical techniques for
monitoring amodiaquine utilization in patients. This study evaluates the field applicability of a new
method to determine amodiaquine and its metabolite concentrations in whole blood dried on filter
paper.
Methods: Twelve patients aged between 1.5 to 8 years with uncomplicated malaria received three
standard oral doses of AQ+AS. Filter paper blood samples were collected before drug intake and
at six different time points over 28 days period. A new field-adapted sampling procedure and liquid
chromatographic method was used for quantitative determination of amodiaquine and its
metabolite in whole blood.
Results: The sampling procedure was successively applied in the field. Amodiaquine could be
quantified for at least three days and the metabolite up to 28 days. All parasites in all the 12 patients
cleared within the first three days of treatment and no adverse drug effects were observed.
Conclusion: The methodology is suitable for field studies. The possibility to determine the
concentration of the active metabolite of amodiaquine up to 28 days suggested that the method is
sensitive enough to monitor amodiaquine utilization in patients. Amodiaquine plus artesunate
seems effective for treatment of falciparum malaria.
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Background
Artemisinin combination therapy (ACT) has been widely
adopted as first-line treatment for uncomplicated falci-
parum malaria [1-3]. Although these drug combinations
appear to be safe and well-tolerated, experience with their
use in Africa is still limited [4,5]. Uganda recently adopted
ACT, whereby artemether + lumefantrine (AL, Coartem®)
was recommended as first-line regimen for treatment of
falciparum malaria. AL, however, has several limitations
including twice-daily dosing regimen and recommenda-
tion to administer the drug together with fatty food [6].
Amodiaquine (AQ) is a 4-aminoquinoline drug that has
demonstrated sustainable efficacy compared to other anti-
malarial drugs [7-9]. In view of low cost and high efficacy,
AQ has been considered as a viable anti-malarial agent
despite reported low risk of agranulocytosis during long
term use [10-13]. Amodiaquine plus artesunate (AQ+AS),
is recommended as an alternative first-line regimen to AL
for the treatment of uncomplicated malaria in Uganda
and many other African countries [14]. Since AQ+AS com-
bination is more affordable than AL, it will most likely
find extensive use in the general population.
Generally, most of the malaria endemic areas are rural.
These areas usually suffer from shortage of resources, for
example electricity, which is required during collection of
samples such as plasma. Furthermore, adsorption and
drying of whole blood samples on filter paper is known to
reduce the risk of exposure to HIV, hepatitis B and C virus,
and other infectious agents [15], thus making sample col-
lection and subsequent handling relatively safe.
Thus, in order perform clinical studies necessary for eval-
uation of AQ+AS impact in such areas, field-adapted sam-
ple collection and robust analytical techniques for
monitoring AQ levels in blood and other body fluids are
needed. Methods for determination of amodiaquine and
its metabolite, desethylamodiaquine (DAQ) from
plasma, whole blood and urine have been reported [16-
18], but until recently there were none, where amodi-
aquine was dried on filter paper under field conditions, all
previous attempts to store AQ on filter paper were futile
[16,17]. The other two filter paper methods reported for
AQ [19,20] were not suitable for field conditions and
were expensive for resource-limited settings.
A new field-adapted filter paper method was recently
developed for determination of amodiaquine from whole
blood spotted on filter paper [21]. The aims of this study
were to explore the practical applicability of the devel-
oped analytical procedure for determination of amodi-
aquine from whole blood dried on filter paper in the field,
and to verify whether the measured drug levels correlate to
the parasite clearance in children on treatment with
AQ+AS combination.
Methods
Study area
The study was conducted in Aduku Health Centre, Apac
District in Northern Uganda between January and Febru-
ary, 2008. Aduku is one of the sentinel sites that were cho-
sen by Uganda Malaria Surveillance Project for evaluating
the efficacy of available anti-malarial therapies and mon-
itoring adverse drug events. It is surrounded by a large
swamp and has very high malaria transmission intensity.
The location is rural and, therefore, possibly has no drug
pressure as there has been no supply of AQ or AS. The
health centre receives free supplies of Coartem® from gov-
ernment for malaria treatment.
Recruitment of patients
Consent forms were administered to all parents/guardians
whose children presented with fever to the study site dur-
ing study period. Patients that consented/assented to par-
ticipate in the study underwent both clinical and
laboratory examination for malaria. Those suffering from
malaria were further screened to exclude cases of compli-
cated malaria (those reported to have had repeated con-
vulsions, unable to feed orally, exhibiting central nervous
system symptoms).
Twelve patients aged between 1.5 to 8 years, having clini-
cally-confirmed acute uncomplicated falciparum malaria,
were recruited into the study and appropriate referrals
were made for the rest. Study participants were followed-
up for 28 days according to World Health Organization
(WHO) protocol [22]. Since this was not a primary effi-
cacy study, no minimum parasitaemia was set for the
inclusion criteria.
Ethical approval
Ethical approval for this study was given by the Makerere
University Research and Ethics Committee and permis-
sion to conduct the study was given by Uganda National
Council of Science and Technology.
Treatment and follow-up procedures
At enrolment, a medical history was taken and a clinical
examination was made. Two venous blood samples were
obtained. One sample was used to obtain solid and con-
sistent readings of the parasites and the other for day zero
drug levels. The children were thereafter orally given AQ
(Amobin®) (Regal Pharmaceuticals Ltd., Nairobi, Kenya)
plus AS (Arinate®) (ERFA n.v./s.a, Brussels) under supervi-
sion. Both Amobin® and Arinate® are made according to
Good Manufacturing Practice (GMP). The medication
dosages were based on the age group as recommended by
the Ministry of Health Uganda [23]. All patients received
standard single daily oral doses of AQ+AS for three days.
Patients aged between one to three years received AQ+AS
(150 mg, 50 mg), while those between four to six years
received AQ+AS (200 mg, 75 mg), and those between sixMalaria Journal 2009, 8:52 http://www.malariajournal.com/content/8/1/52
Page 3 of 5
(page number not for citation purposes)
to 12 years received AQ+AS (300 mg, 100 mg) respec-
tively, on each day.
Patients were asked to return to the Health Centre for fol-
low-up on days 1, 2, 3, 7, 14, 21, 28, and on any other
unscheduled day that they felt sick. Those who did not
return for the scheduled follow-ups were visited at home
on those days. On each visit parasitaemia was determined
from thick blood smears, while 100 μL of phosphoric acid
treated blood was spotted on filter paper for drug level
analysis as described [21]. The thick blood smears were
stained using 2% Giemsa and quantified against 200 leu-
kocytes and parasite densities were recorded as the
number of parasites/200 WBCs.
Sample collection, preparation and analysis
On the day of recruitment (day 0), about 200 to 300 μL of
venous blood samples was collected before treatment and
samples were collected daily thereafter, just before admin-
istration of AQ+AS. Aliquots of collected blood were
mixed with equal amounts of phosphoric acid (10%, v/v)
from which 100 μL was spotted onto filter paper and
allowed to dry at room temperature (23 – 28°C). The fil-
ter paper samples were then stored in plastic envelopes till
analysis. The analysis was carried out as described by
Ntale et al [21].
Thus, filter paper containing dried blood spots was cut
into 4 to 6 small pieces and put into 12 mL polypropylene
test tubes. Subsequently, 150 μL of I.S. solution (0.6 μM)
and 1 mL of water were added and the contents were son-
icated for 15 min. Sodium carbonate buffer (2 mL, 0.2 M,
pH 9.7), KOH (120 μL, 1 M) and 8 mL of di-isopropyl-
ether were added. Final pH of the water phase was
between 9.17 – 9.24. The samples were shaken for 20 min.
and centrifuged for 10 min. at 3500 × g. The organic
(upper) phase was transferred to a new polypropylene test
tube and back-extracted for 10 min. with 150 μL of
sodium dihydrogen phosphate buffer (0.1 M, pH 4). The
phases were separated by centrifugation for 10 min. and
the organic phase was removed by aspiration. The water
phase (130 μL) was injected into the chromatograph.
Results
A total of twelve children participated in the study, with
age ranging between 1.5 to 8 years. There was equal sex
distribution but their weight varied between 7.7 Kg to
25.8 Kg. The AQ dosing was based on age, however, on a
mg/Kg basis the dose ranged from 10.1 to 19.5 (Table 1).
AQ and DAQ concentrations
In all subjects no AQ or DAQ was detected in the pre-dose
blood sample. The AQ level could be measured by day 3
in all subjects, but by day 7 only eight subjects had quan-
tifiable levels. DAQ was quantifiable by day 28 in all sub-
jects with a median concentration of 227 nM (68–1282).
Median AQ levels were highest on day 3, and DAQ levels
followed a similar trend but were higher than those of AQ
at all time points (Table 2 and Figure 1). The lowest
observed concentration for AQ was 178 nM and this was
on day 7, and for DAQ, it was 68 nM observed on day 28,
while the highest concentrations of AQ (5,312 nM) and
DAQ (12,018 nM) were observed on day 3.
Discussion
Due to renewed interest in AQ as a therapeutic agent,
there is a need for a sensitive field-adapted and affordable
analytical method for its determination to enable clinical
pharmacokinetic studies and monitoring of exposure to
AQ in a specific population. Pilot results from an earlier
developed method showed that it was possible to deter-
mine AQ and its main metabolite DAQ concentrations in
Table 1: Characteristics, parasitaemia and AQ daily dose for the 12 children with uncomplicated Plasmodium falciparum malaria
Subject
Characteristics A B C D E F G H I J K L
Age (yrs) 1.5 1.5 1.7 2.3 2.5 2.5 3 3 3 4 8 8
Sex M F M F F F F M M M F M
Weight in Kg 10.2 7.7 11.2 13 11.8 12 13.2 11.7 14.9 16.1 25.8 20.2
AQ Dose (mg/Kg) 14.7 19.5 13.4 11.5 12.5 10.1 12.7 12.8 11.4 12.4 11.6 14.9
Parasitaemia (/200 WBCs)
Day 0 600 7,000 7,500 650 9,000 741 13,000 460 8,000 9,471 400 1,000
Day 1 30 800 1,720 200 721 47 600 4 129 437 7 82
D a y  2 0 00 0 0 000 00 0 2
D a y  3 0 00 0 0 000 00 0 0
D a y  7 0 00 0 0 000 00 0 0
D a y  1 4 00 0000 0 00 000
D a y  2 1 00 0000 0 00 000
D a y  2 8 00 0000 0 00 000Malaria Journal 2009, 8:52 http://www.malariajournal.com/content/8/1/52
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three healthy subjects up to at least 24 hours after drug
intake. This study aimed to assess field applicability of the
sampling procedure as well as the sensitivity of the
method. In addition, the parasite clearance and achieved
drug levels in Ugandan children on treatment with AQ +
AS were analysed.
To control for any anti-malarial drug consumption in the
target population before treatment, AQ and DAQ concen-
trations were measured at day zero (before medication) in
12 whole blood samples collected from all the patients.
The enrolled patients were followed-up for 28 days and
during follow-up, none of the subjects dropped out. The
failure to quantify AQ after seven days in all the subjects
confirmed that the drug was rapidly metabolized to its
active metabolite, DAQ as reported earlier [24].
Although the AQ dose varied from 10.1 to 19.5, there
were no adverse drug reactions observed. The observed
variability in the reported concentrations of AQ and DAQ
could be attributed to differences in body weight of the
study participants and other factors such as nutritional
status and inter-individual genetic variability. This finding
is in agreement with existing literature, which also reveals
considerable variability between patients and healthy
subjects after intravenous infusion with AQ. Post-infusion
plasma concentrations ranging between 231 to 2,352 nM
for AQ have been reported in patients while values
between 180 to 5,400 nM have been detected in healthy
individuals [25,26]. In other studies, it has been reported
that AQ was not detectable in plasma beyond day 3 post-
dose [26-28]. The findings of this study show that AQ was
present in whole blood seven days after drug intake, a
confirmation that whole blood levels of the drug are
higher than the corresponding plasma levels as earlier
reported [28]. This could most probably be explained by
the fact that amodiaquine, like chloroquine, also concen-
trates in the erythrocytes and binds to platelets and leuco-
cytes.
Despite inter-individual variations in AQ and DAQ con-
centrations found in this study, the results demonstrate
that both the sampling and analytical procedure of the
recently developed filter paper method for determination
of AQ and DAQ are applicable in the field. In addition,
the analytical procedure is sufficiently sensitive for the
analysis of low concentrations of both AQ and DAQ in
whole blood dried on filter paper.
It has been suggested earlier that DAQ (and not AQ) must
be monitored in vivo [26]. Therefore, the possibility to
determine desethylamodiaquine up to 28 days with this
method will enable future population-based studies in
countries where amodiaquine in combination with
artesunate have been adopted as an alternative first-line
treatment to AL. The study also adds to the documenta-
tion of AQ levels in children on treatment with AQ+AS.
Although the present study was not powered enough (n =
12) to assess efficacy, it is encouraging that the 28-day fol-
low up indicated 100% parasitological cure for the 12
patients treated with AQ+AS (table 1). This could proba-
bly be explained by the high blood levels of DAQ
achieved during the course of treatment. The high levels of
the metabolite may also be essential in curbing problems
due to re-infections. The results demonstrate that the
AQ+AS combination is still very effective in treating
uncomplicated malaria attacks in children less than eight
years old living in an area of Uganda to which the disease
is highly endemic.
Median concentration-time profile for AQ and DAQ of 12  children on treatment with AQ+AS combination Figure 1
Median concentration-time profile for AQ and DAQ 
of 12 children on treatment with AQ+AS combina-
tion.
Table 2: Whole blood concentrations (median values and range) of AQ and DAQ for children (n = 12) at different times before and 
after administration of AQ+AS
Time (days)
A n a l y t e d 0 d 1d 3d 7 d 1 4 d 2 1 d 2 8
AQ (nmolL-1) 0 321 (115–1696) 1810 (1736–4087) 395 (68–854) 0 0 0
DAQ (nmolL-1) 0 1675 (422–6098) 4850 (1755–12018) 2395 (551–5423) 882 (402–2523) 602 (395–1448) 227 (68–1282)Malaria Journal 2009, 8:52 http://www.malariajournal.com/content/8/1/52
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Conclusion
This study has demonstrated that under field conditions it
is possible to collect and analyse blood samples dried on
filter paper thus making it possible to carry out large scale
study of AQ pharmacokinetics in children with malaria
infection, and to follow-up for any severe adverse reac-
tions related to drug/metabolite concentrations in blood.
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